Abu dhabi: The Institute for Healthier Living Abu Dhabi (IHLAD), renowned as the world's first government-licensed healthy longevity medicine centre, has entered into a partnership with CoreX to develop the UAE's inaugural bio-intelligence engine tailored to a specific population. This initiative leverages artificial intelligence (AI) alongside organ-on-chip biological models, which replicate human organs and tissues, to derive insights directly from human biology. The goal is to enhance drug safety and advance precision medicine with population-specific insights.
According to Emirates News Agency, this collaboration positions the UAE as the first nation globally to implement a bio-intelligence engine that processes biological data based on the indigenous population's human biology, rather than relying on foreign datasets. IHLAD, dedicated to promoting healthier lifestyles through precision diagnostics, lifestyle medicine, and evidence-based therapeutics, joins forces with CoreX, an AI-driven biotech company headquartered in Abu Dhabi.
This pioneering capability will enable the delivery of UAE-relevant insights, supporting safer and more informed decision-making regarding medication use. By more accurately predicting patient responses to medications, it aims to reduce avoidable reactions, identify risks early, and guide personalized treatment plans.
Furthermore, the initiative paves the way for more representative drug development, allowing pharmaceutical companies to evaluate medicines against biology that mirrors the UAE's genuine genetic, metabolic, and clinical characteristics. This effort not only improves health outcomes for UAE residents but also bolsters national health security, underscoring Abu Dhabi's scientific infrastructure as a hub for global pharmaceutical and research collaborations.
As IHLAD becomes the institutional anchor for CoreX in the UAE, the new capability is set to attract global pharmaceutical, biotech, and life-science companies seeking human-relevant models for safe, efficient, and locally reflective drug discovery. This supports the UAE's strategy to cultivate a secure, future-ready biomedical ecosystem.
The bio-intelligence engine will be constructed through a phased, multimodal AI platform integrating patient-specific organoid and organ-on-chip models, along with biological, molecular, and functional Bio-AI data. It will also incorporate population-specific biological data, including Emirati and regional datasets, to form a predictive system that enhances drug-response modeling, enables precision medicine at scale, and develops a secure national biological-intelligence dataset.
Dr. Nicole Sirotin, CEO of IHLAD, expressed that the partnership with CoreX aims to merge advanced AI with patient-specific organ-on-chip models to achieve more precise predictions for the Emirati population and the broader community. Dr. Isaac Bentwich, Founder and Global CEO of CoreX, highlighted that the partnership will create a platform grounded in scientific rigor, population relevance, and predictive insight, serving the region for generations.
Sarah Miller, Co-Founder, President, and GCC Lead of CoreX, emphasized that the UAE is pioneering a national engine where AI learns from organ-on-chip human biology at a population scale. This collaboration moves beyond foreign datasets to build a national resource capable of shaping the future of safer, more precise medicine, enhancing Emirati wellbeing, and redefining global healthcare possibilities.
Together, IHLAD and CoreX are reinforcing Abu Dhabi's leadership in longevity, precision health, and next-generation medical innovation, contributing to the global transition towards human-centric healthcare. The platform adheres to UAE cultural and ethical standards, utilizing cells from consenting adults without involving embryos, foetal tissue, cloning, mixing, or genetic modification. All operations occur in licensed UAE facilities, focusing exclusively on drug safety and reducing the reliance on animal testing.